ProCE Banner Activity


Bridging the Gap in Pulmonary Arterial Hypertension in Connective Tissue Disease: Promoting Consistent Screening and Management Regimens


Among patients with connective tissue disease (CTD), the highest prevalence of pulmonary arterial hypertension (PAH) occurs in those with systemic sclerosis and is associated with poorer survival outcomes. Therefore, early identification and appropriate treatment are imperative to help improve survival in patients with CTD-PAH. In this 1-hour webcast, national PAH experts detail screening approaches for earlier identification of CTD-PAH and discuss current recommendations for designing individualized treatment regimens for improved patient outcomes.

In Collaboration With the Association of Pulmonary Advanced Practice Providers


Physician Assistants: maximum of 1.00 hours of AAPA Category 1 CME credits Registered Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacology credit

Released: January 28, 2022

Expiration: January 27, 2023

No longer available for credit.



Kristin B. Highland

Kristin B. Highland, MD, MSCR

Rheumatic Lung Disease Program
Cleveland Clinic
Cleveland, Ohio

Martha Kingman

Martha Kingman, FNP-C, DNP

Nurse Practitioner
Pulmonary Hypertension Clinic
University of Texas Southwestern Medical Center
Dallas, Texas

Corinne Young

Corinne Young, MSN, FNP-C, FCCP

The Association of Pulmonary Advanced Practice Providers
Colorado Springs, Colorado


This program is cosupported by educational grants from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson; Genentech, a member of the Roche Group; GlaxoSmithKline; Jazz Pharmaceuticals, Inc.; and Mylan Specialty L.P.

This activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.

Provided by

ProCE Banner

Target Audience

NPs and PAs in pulmonary medicine

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Characterize the symptoms and signs of CTD-PAH and the screening algorithms indicated for early identification and initiation of appropriate treatment

  • Summarize current treatment recommendations for PAH

  • Formulate treatment regimens that are individualized to patients with CTD-PAH


Dr Highland: contracted research: Gossamer Bio, Reata, Viela Bio; contracted research/consulting fees: Acceleron; contracted research/consulting fees/fees for non-CME/CE services: Boehringer Ingelheim, United Therapeutics; contracted research/fees for non-CME/CE services: Bayer.

Dr Kingman: consulting fees: Acceleron, Aerovate, Bayer, Janssen (Actelion), United Therapeutics.

Ms Young has no relevant financial relationships to disclose.

None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.

Instructions for Credit

Participants wishing to earn CE/CME credit must:

  1. View the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete the evaluation form

The estimated time to complete this activity is 1.00 hour.

Release date: January 28, 2022
Expiration date: January 27, 2023


Interactive video lecture


The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.



Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit

AAPA Credit Designation

Joint AccreditationPracticing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until January 27, 2023. PAs should only claim credit commensurate with the extent of their participation.

PA course advisor: John Hardisty, MS, MSPAS, PA-C, Colorado Springs Pulmonary Consultants, Colorado Springs, Colorado

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

Additional Information

Program Medium

This program has been made available online.